伊诺妥珠单抗奥唑米星标准与替代给药方案治疗复发难治性儿童B-ALL的真实世界多中心经验
该多机构回顾性分析纳入72例接受至少一剂伊诺妥珠单抗奥唑米星(InO)的儿童、青少年及年轻成人复发难治性B细胞急性淋巴细胞白血病(B-ALL)患者,其中41例标准给药、31例替代给药。标准给药与更高的复合完全缓解(CRc)相关,但两组在能否桥接至巩固性细胞治疗及2年无事件生存或总生存上无差异。
要点
- 标准InO给药与更高CRc相关,但替代给药在桥接移植及生存上无差异。
- 替代给药策略可成功桥接至巩固治疗,结局与标准给药相当。
核心结论
- 在儿童/AYA复发难治性B-ALL中,替代InO给药策略可成功桥接至巩固治疗,结局与标准给药无差异。
研究设计与样本
- 多机构回顾性分析纳入72例接受至少一剂InO的儿童、青少年及年轻成人R/R B-ALL患者,标准给药41例,替代给药31例。
主要发现
- 标准给药与改善的复合完全缓解(CRc)相关。
- 两组在能否进行巩固性细胞治疗上无差异。
- 两组2年无事件生存和总生存无差异。
- SOS多数病例见于标准InO给药组,但因病例数少尚不能确定与给药方案差异有关。
临床怎么用
- 替代InO给药策略可作为桥接巩固治疗的可行选择,不劣于标准给药。
局限性
- 回顾性设计,样本量有限(72例),SOS病例少难以比较给药方案差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inotuzumab ozogamicin (InO) is approved by the U.S. Food and Drug Administration (FDA) for relapsed/refractory (R/R) B-cell acute lymphoblastic leukaemia (B-ALL), with a standard schedule of 1.8 mg/m2 fractionated into three doses for cycle 1. Alternative dosing with fewer doses or lower cumulative doses may be considered to minimize toxicity or expedite transition to consolidative therapy, though data on the efficacy and toxicity of this approach are limited. We conducted a multi-institutional retrospective analysis of 72 paediatric, adolescent and young adult (AYA) patients receiving at least one InO dose; 41 with standard dosing and 31 with alternative dosing. Between the two approaches, standard dosing was associated with improved composite complete response (CRc); however, there was no difference in ability to proceed to consolidative cellular therapy, nor differences in 2-year event-free or overall survival. Ten per cent of patients experienced sinusoidal obstruction syndrome (SOS), all following haematopoietic stem cell transplant. Most cases occurred in patients receiving standard InO dosing; however, given the overall few cases, it is unclear if this is due to a difference in dosing regimen. In conclusion, this large real-world study of InO use in the paediatric/AYA R/R B-ALL population suggests using alternate InO dosing strategies can successfully bridge patients to consolidative therapy with no difference in outcomes compared with standard dosing.
引用
- Drucker M, Lane A, Aftandilian C, et al. A real-world multi-institution experience of standard versus alternative dosing regimens of inotuzumab ozogamicin for relapsed/refractory paediatric B-cell acute lymphoblastic leukaemia. Br J Haematol. 2026. PMID: 42899382. doi:10.1111/bjh.70892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。